Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine

  title={Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine},
  author={Michel E. Bertrand and Charalambos Vlachopoulos and Jean-Jacques Mourad},
  journal={American Journal of Cardiovascular Drugs},
Statins, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCBs) have markedly changed the clinical progression of patients with coronary artery disease (CAD). The goal of this paper is to review the rationale and evidence for combining these three drug classes in hypertensive patients with hypercholesterolemia or CAD. Data sources include a literature search for publications on the use of a statin combined with various antihypertensive drugs in patients with… 

Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy

Real-world analysis among patients with free combination therapy can be applied to estimate the eligible population for fixed combination, and to evaluate the appropriateness of their prescriptions.

Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice

The perindopril/amlodipine FDC is characterized by high adherence and effectiveness, regardless of previous treatment, and was related to baseline BP levels.

Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension

Overall, early intervention in patients with hypertension with use of an effective, high-intensity cardiovascular risk reduction regimen and attention to medication adherence through reducing pill burden are likely to result in optimal outcomes.

Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies

CKD and ESRD patient groups faced significantly higher risk of stroke and post-stroke mortality, and were significantly higher in both sexes and every age group.

Simultaneous Determination of Telmisartan and Pitavastatin calcium in Intestinal Perfusate by HPLC: Application to Intestinal Absorption Interaction Study.

Results showed telmisartan and pitavastatin calcium were transported passively, and tel Misartanand pitavASTatin calcium could be absorbed well in all intestinal segments, and the intestinal absorption parameters revealed the absence of any intestinal absorption interaction when co-administered.

Ocena skuteczności leczenia hipotensyjnego pacjentów z nadciśnieniem tętniczym i chorobą niedokrwienną serca lub ekwiwalentem wieńcowym

It was revealed that main factors affecting poor blood pressure control after six months of observation were: obesity, age > 65 years, LDL cholesterol level > 130 mg/dL, and diabetes, which was more frequent in patients with diabetes mellitus.

The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

It is demonstrated that an algorithm reflecting the degree to which patients were matched to the drugs administered correctly ranked the response to the regimens with a specificity of 77%.

Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study

  • C. Dézsi
  • Medicine, Biology
    The Journal of international medical research
  • 2018
Subgroup analyses of the previously published Hungarian Perindopril plus Amlodipine in PAtients with Coronary Artery Disease (PAPA-CAD) non-interventional trial demonstrated that the addition of the metabolically beneficial, fixed combination of perIndopril’+ amlodipines to atorvastatin further improves the patient’s lipid profile.

Effect of intensive multifactorial treatment on vascular progenitor cells in hypertensive patients

Long-term intensive treatment in hypertensive patients further improves cardiovascular risk and increases circulating EPCs, suggesting that these cells could be a therapeutic target.



Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine

Evidence for the fixed combination of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the calcium channel blocker amlodipine indicates it as a credible option for the optimization of the management of hypertension and CAD.

Atorvastatin calcium plus amlodipine for the treatment of hypertension

The use of the single-pill amlodipine and atorvastatin is an adequate option for the clinician to treat hypertensive patients with DYL or high CV risk burden, with proven efficacy, tolerability, cost-effectiveness, and the advantage of improving patient treatment compliance.

Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

The statin+ACEI combination reduces cardiovascular events more than a statin alone and considerably more than an ACEI alone.

Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine

A strategy using ACE inhibitors and CCBs, such as perindopril and amlodipine, to target multiple stages in both pathways of cardiovascular disease could effectively reduce cardiovascular risk and lower BP.

Hypertension management: rationale for triple therapy based on mechanisms of action.

This review discusses the triple-therapy combination of an angiotensin receptor blocker (ARB) or direct renin antagonist (DRI) with a calcium channel blocker (CCB) and a diuretic, with a focus on mechanisms of action.

Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta‐Analysis in 20,451 Hypertensive Patients

A+C therapy is superior to other combinations of antihypertensive treatment as it shows a lower incidence of cardiovascular events and adverse events, while it has similar effects in lowering BP and preserving renal function.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.